Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$36.83 USD
-1.53 (-3.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.80 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.83 USD
-1.53 (-3.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.80 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
Zacks News
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Longboard Pharmaceuticals (LBPH) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
by Zacks Equity Research
Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
by Zacks Equity Research
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)
by Zacks Equity Research
Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 262.5% upside potential for Longboard Pharmaceuticals, Inc. (LBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Longboard Pharmaceuticals, Inc. (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
by Zacks Equity Research
Longboard Pharmaceuticals, Inc. (LBPH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Longboard Pharmaceuticals, Inc. (LBPH) Have the Potential to Rally 208.22% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Longboard Pharmaceuticals, Inc. (LBPH) points to a 208.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict an 184.81% Upside in Longboard Pharmaceuticals, Inc. (LBPH): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Longboard Pharmaceuticals, Inc. (LBPH) points to an 184.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Longboard Pharmaceuticals, Inc. (LBPH) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Longboard Pharmaceuticals, Inc. (LBPH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.